Physician profile

John Michael Lyons

Obstetrics & Gynecology · Colton, CA

NPI 1215905930

$462.47

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$33.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $203.88 2019-2020
Medtronic, INC. $142.88 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $44.57 2019-2021
Astellas Pharma US INC $33.59 2023 Veozah
Coopersurgical, INC. $13.21 2019
Braintree Laboratories, INC. $12.82 2019
Merck Sharp & Dohme LLC $11.52 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Michael Lyons

$462.47

in general payments reported 2019-2025

Years
2019-2023
Top company
Takeda Pharmaceuticals U.S.A., INC.

https://glasscript.com/doctor/100072/john-michael-lyons

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.